第一代与第二代抗精神病药迟发性运动障碍风险的随机对照试验荟萃分析
该荟萃分析纳入57项头对头随机对照试验,比较第二代抗精神病药(SGA)与第一代抗精神病药(FGA)及SGA之间迟发性运动障碍(TD)风险。结果显示SGA的TD风险及年化发生率均显著低于FGA,且不同SGA之间风险存在差异,奥氮平和阿立哌唑相对其他非氯氮平SGA具有优势。
要点
- SGA的TD风险显著低于FGA,RR=0.47,NNT=20。
- FGA组年化TD发生率为6.5%,SGA组为2.6%。
- 奥氮平在SGA间比较中TD风险显著低于非氯氮平SGA。
核心结论
- SGA相比FGA具有临床意义上更低的TD风险,且该差异并非由高剂量FGA对照驱动。
- 不同SGA之间的TD风险存在显著差异,奥氮平和阿立哌唑在探索性比较中显示优势。
研究设计与样本
- 荟萃分析纳入57项头对头随机对照试验,包括32个FGA组和86个SGA组,形成32对FGA-SGA比较和35对SGA-SGA比较。
主要发现
- FGA组年化TD发生率为6.5%(95% CI: 5.3-7.8%),SGA组为2.6%(95% CI: 2.0-3.1%)。
- SGA vs. FGA的TD风险RR=0.47(95% CI: 0.39-0.57, p<0.0001, k=28),年化率比RaR=0.35(95% CI: 0.28-0.45, p<0.0001, NNT=20)。
- Meta回归显示FGA剂量对FGA-SGA比较无影响(Z=-1.03, p=0.30)。
- FGA-SGA的TD年化率比因SGA对照不同而异(Q=21.8, df=7, p=0.003),探索性 pairwise 比较中奥氮平和阿立哌唑相对其他非氯氮平SGA有显著优势。
- SGA-SGA比较证实奥氮平相对非氯氮平SGA的优势(RaR=0.66, 95% CI: 0.49-0.88, p=0.006, k=17, NNT=100)。
关键数值与推荐
- SGA vs. FGA的TD风险RR=0.47(95% CI: 0.39-0.57, p<0.0001),年化率比RaR=0.35(95% CI: 0.28-0.45, p<0.0001),NNT=20。
- 奥氮平 vs. 非氯氮平SGA的TD年化率比RaR=0.66(95% CI: 0.49-0.88, p=0.006, k=17),NNT=100。
临床怎么用
- 临床选择抗精神病药时,SGA的TD风险总体低于FGA,可优先考虑SGA以降低TD风险。
- 在SGA中选择时,奥氮平和阿立哌唑的TD风险相对其他非氯氮平SGA更低,可作为个体化决策参考。
局限性
- 原文未明确报告纳入研究的偏倚风险、异质性来源及随访时长等局限性细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tardive dyskinesia (TD) risk with D2/serotonin receptor antagonists or D2 receptor partial agonists (second-generation antipsychotics, SGAs) is considered significantly lower than with D2 antagonists (first-generation antipsychotics, FGAs). As some reports questioned this notion, we meta-analyzed randomized controlled studies (RCTs) to estimate the risk ratio (RR) and annualized rate ratio (RaR) of TD comparing SGAs vs. FGAs and SGAs vs. SGAs. Additionally, we calculated raw and annualized pooled TD rates for each antipsychotic. Data from 57 head-to-head RCTs, including 32 FGA and 86 SGA arms, were meta-analyzed, yielding 32 FGA-SGA pairs and 35 SGA-SGA pairs. The annualized TD incidence across FGA arms was 6.5% (95% CI: 5.3-7.8%) vs. 2.6% (95% CI: 2.0-3.1%) across SGA arms. TD risk and annualized rates were lower with SGAs vs. FGAs (RR=0.47, 95% CI: 0.39-0.57, p<0.0001, k=28; RaR=0.35, 95% CI: 0.28-0.45, p<0.0001, number-needed-to-treat, NNT=20). Meta-regression showed no FGA dose effect on FGA-SGA comparisons (Z=-1.03, p=0.30). FGA-SGA TD RaRs differed by SGA comparator (Q=21.8, df=7, p=0.003), with a significant advantage of olanzapine and aripiprazole over other non-clozapine SGAs in exploratory pairwise comparisons. SGA-SGA comparisons confirmed the olanzapine advantage vs. non-clozapine SGAs (RaR=0.66, 95% CI: 0.49-0.88, p=0.006, k=17, NNT=100). This meta-analysis confirms a clinically meaningfully lower TD risk with SGAs vs. FGAs, which is not driven by high dose FGA comparators, and documents significant differences with respect to this risk between individual SGAs.
引用
- Carbon M, Kane JM, Leucht S, et al. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018. PMID: 30192088. doi:10.1002/wps.20579
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。